TheraSphere real-world evidence shaping multidisciplinary HCC care panel discussion
This VuMedi Product Workshop video highlights the PROACTIF HCC results through a panel discussion, showcasing findings from the largest prospective, real-world Y-90 study in hepatocellular carcinoma. The presentation reviews survival outcomes across BCLC stages, findings in complex patient populations, and the impact of personalized dosimetry, including higher absorbed doses (≥400 Gy). It also explores multidisciplinary treatment considerations and how PROACTIF data may help inform patient selection and treatment planning.